Titles
- How does the Trump Administration drug pricing blueprint affect Medicaid?1
- How prescription drug use affects health care utilization and spending by older Americans: a review of the literature1
- How state Medicaid programs are managing prescription drug costs: results from a state Medicaid pharmacy survey for state fiscal years 2019 and 20201
- How to strengthen the Medicaid Drug Rebate Program to address rising Medicaid prescription drug costs1
- How will the Medicare Part D benefit change under current law and leading proposals?1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Insurance market reform: 1
- MAT for hospitalized patients1
- Making drug costs more transparent to consumers: a summary for policymakers1
- Management of patients with opioid dependence: a review of clinical, delivery system, and policy options1
- Medicaid's most costly outpatient drugs1
- Medicare Part D1
- No limit: Medicare Part D enrollees exposed to high out-of-pocket drug costs without a hard cap on spending1
- PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks : final report1
- Prescription drugs and Medicare Part D: a report on access, satisfaction, and cost1
- Prescription drugs in Nebraska: a survey of experiences and opinions1
- Quality of healthcare1
- Reducing potential overuse of dementia drugs could lead to considerable savings1
- Searching for savings in Medicare drug price negotiations1
- Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update1